AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20575654
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone (NP) per vagina at 200 mg/day
Trial: 20575654
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone (NP) per os at 100 mg/day
Trial: 20575654
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone (NP) per os at 200 mg/day
Trial: 16547380
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution with glutamine dipeptide (20% of total amino acids)
Trial: 3079994
Drug: Standard amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard amino acid solution
Trial: 11465341
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement (1 to 2 U GH/day) for 6 months, followed by 2 U GH/day for an additional 6 months.
Trial: 3395542
Drug: MST 60
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MST 60 mg and hyoscine 0.6 mg
Trial: 28617566
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) 3,000 mg daily
Trial: 21527594
Drug: Oral synbiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral synbiotics (Bifidobacterium, Lactobacillus, and galactooligosaccharides) preoperatively for 14 days and postoperatively for 11 days
Trial: 18467280
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with prophylactic EPO therapy
Trial: 12953793
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of HCA
Trial: 8892452
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy total dose extended field radiotherapy (EF‐RT) plus 10 Gy total dose involved field radiotherapy (IF‐RT)
Trial: 3902531
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once daily
Trial: 29776112
Drug: Tensor renormalization
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tensor renormalization group algorithm with randomized singular value decomposition; specific details on dosage and duration not applicable.
Trial: 24035407
Drug: Risperidone (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (target dose 1.5 mg)
Trial: 22911284
Drug: Group Exercise
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Exercise Program (GI) - strength, balance, and functional mobility exercises, 50 minutes, twice a week for 4 months
Trial: 22911284
Drug: Stretching Exercises
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stretching Exercises (GC) - 50 minutes, twice a week for 4 months
Trial: 20856886
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in plasma HIV-1 RNA by 0.74 log(10) copies/mL
Trial: 20856886
Drug: Baseline plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plasma HIV-1 levels ≥4 log(10) copies/mL
Trial: 12581050
Drug: Intravenous pyelography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pyelography (IVP)
Trial: 12690415
Drug: 131I-lipiodol therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I-lipiodol therapy with a mean activity of 1.9 GBq (SD 0.2)
Trial: 12690415
Drug: 131I-lipiodol therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I-lipiodol therapy with potassium iodide (KI) thyroid blocking
Trial: 12690415
Drug: Biological dosimetry
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological dosimetry using the in vitro micronucleus (MN) assay
Trial: 8946272
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg dexfenfluramine twice daily
Trial: 2014076
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) 3‐mg pessaries 4 hours apart, followed by oxytocin infusion if necessary
Trial: 25181622
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin infusion
Trial: 6368424
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rifampin (RMP) 600 mg and ethionamide (ETH) 500 mg
Trial: 6368424
Drug: RMP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP administered twice a week for three months
Trial: 6368424
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of daily dose of ETH or reduction of duration of RMP + ETH
Trial: 27484673
Drug: 1064-nm laser
RxNorm normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1064-nm laser treatment
Trial: 8758083
Drug: Chloroquine (CHL)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CHL) 25 mg/kg over 3 days
Trial: 8758083
Drug: Sulfadoxine (SDX)
RxNorm normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine (SDX) 25 mg/kg plus Pyrimethamine (PYR) 1.25 mg/kg (statim dose)
Trial: 29605216
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS)
Trial: 31744837
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) with longer time (>4 years) since initiation
Trial: 31744837
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) with higher mean daily dose (>1000 μg fluticasone equivalents)
Trial: 27797683
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) 500 mg daily for 4 weeks
Trial: 26029855
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (3 g per day, 1 g before each meal) with a low-calorie diet
Trial: 21442805
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in the control group (20 cases)
Trial: 11929402
Drug: Celecoxib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (800 mg/day)
Trial: 9390588
Drug: Nicardipine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 0.5 mg
Trial: 7910722
Drug: GLQ223 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLQ223 administered intravenously at doses of 36 and 50 micrograms/kg
Trial: 7910722
Drug: GLQ223 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLQ223 administered intravenously at doses of 8, 16, 24, 36, and 50 micrograms/kg
Trial: 7910722
Drug: GLQ223 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLQ223 administered intravenously
Trial: 31578080
Drug: Lp(a) lowering
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) lowering by 50 mg/dL (105 nmol/L) for 5 years
Trial: 31578080
Drug: Lp(a) lowering
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) lowering by 99 mg/dL (212 nmol/L) for 5 years
Trial: 31578080
Drug: Individuals with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals with Lp(a) 10 to 49 mg/dL (18-104 nmol/L)
Trial: 14586387
Drug: Cigarette smoking
RxNorm normalized name: Cigarette smoking tobacco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette smoking (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Trial: 14586387
Drug: Carbon monoxide
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon monoxide (7 days, 250 mg chlorzoxazone and 250 mg caffeine)
Trial: 10740559
Drug: Lidocaine 30
RxNorm normalized name: lidocaine 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 30 mg pretreatment
Trial: 31806099
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 3 months
Trial: 31806099
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg/d for 3 months (after initial no treatment)
Trial: 26581199
Drug: recMAGE-A3 combined
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recMAGE-A3 combined with AS15 immunostimulant administered intramuscularly (group A, n=13)
Trial: 26581199
Drug: recMAGE-A3 combined
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recMAGE-A3 combined with AS15 immunostimulant administered intradermally/subcutaneously (group B, n=12)
Trial: 24814583
Drug: Perioperative selective
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative selective decontamination of the digestive tract (SDD) with colistin, tobramycin, and amphotericin B in addition to standard antibiotic prophylaxis
Trial: 8826973
Drug: 2-h insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-h insulin levels in individuals who developed NIDDM
Trial: 8047423
Drug: 2% nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nitroglycerin ointment
Trial: 3105368
Drug: Bland ointment
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bland ointment
Trial: 20151940
Drug: Zinc and
RxNorm normalized name: Zinc and/or zinc compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc and vitamin A supplementation (10 mg elemental zinc per day and one-half of a 25,000 IU vitamin A tablet every other day)
Trial: 12648639
Drug: Group 2c
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2c (in-the-bag IOL implantation without opening the posterior capsule)
Trial: 7871449
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin
Trial: 1493986
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg ciprofloxacin
Trial: 2811556
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of intravenous dexamethasone before the procedure
Trial: 1108720
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of terbutaline
Trial: 1108720
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of metaproterenol
Trial: 31712211
Drug: CVC lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CVC lock solution with taurolidine‐citrate‐heparin
Trial: 29720244
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone (placebo)
Trial: 30778572
Drug: L-OTM (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-OTM (equivalent to L-ITM)
Trial: 24517059
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Jinhua Qinggan Granule (5 g JHG + 5 g placebo each time, 3 times daily for 5 days)
Trial: 24517059
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (10 g placebo each time, 3 times daily for 5 days)
Trial: 21499183
Drug: Real-time continuous
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time continuous glucose monitor with intravenous insulin infusion and rescue glucose (tight glycemic control arm)
Trial: 19228385
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment every four months for 12 months
Trial: 19228385
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment every four months for 12 months
Trial: 19228385
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment at baseline
Trial: 9267682
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg under fasting conditions
Trial: 3299441
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of caffeine and mental arithmetic
Trial: 3299441
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of caffeine alone
Trial: 28561421
Drug: Etofenamate patch
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofenamate patch
Trial: 25724656
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (2 μg/kg, n=10)
Trial: 14594787
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg elemental calcium daily for 12 months)
Trial: 1395211
Drug: Enalapril (ACE-I)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (ACE-I) added to conventional therapy including digitalis, diuretics, or vasodilators
Trial: 6347233
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg orally daily for 2 weeks
Trial: 26900078
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg aripiprazole
Trial: 24859440
Drug: Ultralow dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow dose computerized tomography (model based iterative reconstruction)
Trial: 15188499
Drug: H pylori-positive
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori-positive NUD patients receiving 10-day triple eradication therapy
Trial: 9491847
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy regimen
Trial: 4278962
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine solution
Trial: 4278962
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical lidocaine
Trial: 19616778
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of oral misoprostol immediately after evacuation followed every 6 hours for 48 hours
Trial: 15570414
Drug: Biochemical markers
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical markers of bone turnover (serum osteocalcin, bone-specific alkaline phosphatase, deoxypyridinoline, pyridinolines, type I collagen cross-linked C-terminal telopeptide, serum intact parathyroid hormone, 1,25 dihydroxy vitamin D)
Trial: 10669269
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion with bupivacaine 1 mg/ml and fentanyl 10 mg/ml (F10)
Trial: 3896217
Drug: Terbutaline by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline by wet nebulisation (5 mg, four times daily)
Trial: 24576866
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (Ca-fortified beverage, 1 g·L)
Trial: 12821556
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800 IU and Vitamin C 1 g before breakfast
Trial: 12821556
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800 IU and Vitamin C 1 g (timing not specified)
Trial: 8929748
Drug: Metoprolol controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol controlled release tablet (100 mg)
Trial: 8929748
Drug: Bisoprolol normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol normal release tablet (10 mg)
Trial: 20861631
Drug: Acid etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid etching treatment (E)
Trial: 20861631
Drug: No acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No acid etching treatment (NE)
Trial: 15896425
Drug: Whole formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole formula diet based on lyophilised foods (Treatment Group)
Trial: 84532
Drug: Protected environment-prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protected environment-prophylactic antibiotic (PEPA) program
Trial: 30666480
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) with Ketac Molar Easymix® (3 M ESPE)
Trial: 30666480
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) with Vitro Molar® (DFL)
Trial: 19827462
Drug: Delayed Feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Feeding (DF): Water immediately postexercise, CHO-PRO solution 1 hr postexercise
Trial: 19827462
Drug: Control (CON):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CON): Water (12 ml/kg BM) immediately and 1 hr postexercise
Trial: 9853540
Drug: Psyllium (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (1.3 g/day of soluble fiber)
Trial: 9853540
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (2.6 g/day of soluble fiber)
Trial: 8299777
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IV Ig)
Trial: 23669452
Drug: Parent-led tactile
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-led tactile stimulation (rubbing the ipsilateral thigh distal to the site for 15 seconds before, during, and after injections)
Trial: 23537313
Drug: Weekly (W)
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly (W) schedule with gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W
Trial: 23537313
Drug: 3-weekly (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly (3 W) schedule with gemcitabine 1250 mg/m2 Day 1,8 + paclitaxel 175 mg/m2 Day 1 q3W
Trial: 23537313
Drug: Weekly (W)
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly (W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Trial: 23537313
Drug: 3-weekly (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly (3 W) schedule with gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W
Trial: 11692899
Drug: Prednisolone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.75 mg/kg for six months)
Trial: 14635083
Drug: Dolasetron 100
RxNorm normalized name: dolasetron 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 100 mg
Trial: 9398956
Drug: Dolasetron 200
RxNorm normalized name: dolasetron 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 200 mg
Trial: 3296260
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with irradiation
Trial: 24710760
Drug: Colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.75 g/day
Trial: 17500381
Drug: Etanercept therapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept therapy
Trial: 10856099
Drug: Chemotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (specific dosage and duration not mentioned)
Trial: 31816352
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid)
Trial: 31816352
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablets (ODTs) with water-insoluble radiolabel (technetium-99 m-labeled ion exchange resin)